News

Sustainable Innovation: CARBIOS Partners with Selenis for PETG

Sustainable Innovation: CARBIOS Partners with Selenis for PETG

CARBIOS and Selenis Forge a Trailblazing Alliance in Sustainability

CARBIOS, an innovative biotech firm dedicated to reshaping the life cycle of plastics, has teamed up with Selenis, a leading provider of specialized polyester solutions. This partnership marks an exciting new chapter in the production of polyethylene terephthalate glycol (PETG), made possible through CARBIOS' groundbreaking biorecycling technology, specifically tailored for the Cosmetic and Healthcare packaging sectors.

Why is PETG So Important?

PETG is an essential material widely used in both cosmetics and healthcare packaging. It’s well-loved for its remarkable clarity and exceptional durability. With strong resistance to both mechanical and chemical stresses, PETG proves to be perfect for a variety of applications. At the heart of this production process lies CARBIOS' innovative enzymatic depolymerization technology, which transforms diverse PET waste into vital building blocks like purified terephthalic acid (PTA) and monoethylene glycol (MEG). These monomers are then polymerized using advanced Selenis techniques to produce high-quality PETG.

Advantages of Biorecycling

The collaboration between CARBIOS and Selenis is geared towards producing PETG that matches the performance of virgin PETG while weaving sustainability into its core. This biorecycled PETG meets rigorous performance standards essential for industries where sterility and transparency are paramount. As a result, it's particularly well-suited for the packaging of medical devices, pharmaceuticals, and diagnostic tools. Additionally, with consumer preferences shifting toward sustainable options, this partnership effectively marries cutting-edge technology with responsible practices.

Continuing the Journey Together

The foundation of this partnership is built on two years of joint efforts to refine and enhance PETG production through pilot programs and industrial polymerization trials. This extensive research and development has laid a strong groundwork for creating high-quality specialty PETG grades tailored for both cosmetic and healthcare uses. Through its Selcare brand, Selenis has established a reputation for excellence in these critical sectors, focusing on high-quality medical-grade plastics.

Insights from Company Leaders

Emmanuel Ladent, CEO of CARBIOS, expressed his excitement about their long-standing collaboration, stating, “This high-specialty, premium material meets demanding quality requirements whilst also contributing to the transition to more sustainable packaging materials.” His remarks illustrate the emphasis on boosting commercial opportunities within the healthcare domain.

Eduardo Santos, the Head of Corporate Strategy at Selenis, also shared his thoughts on their initiatives, pointing out, “...we are advancing in the development of sustainable materials to meet the growing demand for environmentally responsible solutions.” Through the combination of both companies' expertise, their goal is to redefine the future landscape of sustainable plastics.

The Larger Contribution of CARBIOS and Selenis to Sustainability

CARBIOS has garnered notable recognition for its innovative strategies in combating plastic and textile waste, effectively employing enzyme-based technologies to foster a circular economy. Their operational biorecycling demonstration plant has been functioning successfully since 2021, and they are currently developing an industrial facility in collaboration with Indorama Ventures.

In a similar vein, Selenis is dedicated to crafting innovative polyester solutions that not only cater to market demands but are also environmentally friendly. They’re focused on creating resins that contain a significant percentage of recycled materials, which fit seamlessly within the PET recycling chain.

The Road Ahead

The ongoing collaboration between CARBIOS and Selenis signals a significant transition toward sustainable practices within the polymerization field. As they continue to innovate together, their products and solutions will play a crucial role in tackling plastic waste challenges and promoting a more sustainable future.

Frequently Asked Questions

What is CARBIOS known for?

CARBIOS is recognized for its pioneering efforts in developing biological technologies aimed at transforming the lifecycle of plastics and textiles.

How does PETG produced by CARBIOS and Selenis compare to traditional PETG?

The PETG produced through this partnership matches the properties of virgin PETG while being derived from recycled materials, making it more sustainable.

What sectors are impacted by this collaboration?

This partnership significantly impacts the Cosmetic and Healthcare sectors by providing sustainable packaging solutions.

What technologies are utilized in this partnership?

The partnership utilizes CARBIOS' enzymatic depolymerization technology and Selenis' polymerization methods to produce PETG from PET waste.

Where can I find more information about CARBIOS?

For further details about CARBIOS and its initiatives, please visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles